C60 and Parkinson’s 

Buckminsterfullerene (C60) derivatives are a unique class of compounds with potent antioxidant properties. Studies  indicated that they are capable of eliminating both superoxide anion and H2O2, and were effective inhibitors of lipid peroxidation. Carboxyfullerenes demonstrated robust neuroprotection against excitotoxic, apoptotic and metabolic insults in cortical cell cultures.  Although there is limited in vivo data on these compounds to date. Ongoing studies in other animal models of CNS disease states suggest that these novel antioxidants are potential neuroprotective agents for other neurodegenerative disorders, including Parkinson’s disease.

Moreover, we report that C₆₀(OH)₃₆ at the concentrations of 60 μM and 80 μM is capable of producing epilepsy in the HPC in vitro, which suggests that C₆₀(OH)_n, when applied at higher doses, may have a deleterious effect on the functioning of neuronal networks.

Here is some studies that researchers have done on C60 and Parkinson’s,as more studies come up we will add them to this page.

Fullerene-based antioxidants and neurodegenerative disorders

https://www.thebronxproject.com/Articles/8.)%20%20Parkinsons%20and%20Related%202001.pdf 

Fullerenol C₆₀(OH)₃₆ at relatively high concentrations impairs hippocampal theta oscillations (in vivo and in vitro) and triggers epilepsy (in vitro) – A dose response study.

httpss://www.ncbi.nlm.nih.gov/pubmed/29909157 

Adsorption of ascorbic acid on the C60 fullerene.

httpss://www.ncbi.nlm.nih.gov/pubmed/18939786

Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) -induced cellular model of Parkinson’s disease.

httpss://www.ncbi.nlm.nih.gov/pubmed/18709653